

**Acknowledgement and Consent for Disclosure of
A Waiver Under 18 U.S.C. §208(b)(3)**

Peter Gross, M.D.

Committee: Drug Safety and Risk Management Advisory
Committee

Meeting Date: February 10, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda items (1) briefing on developments in the Office of Drug Safety; (2) updates on the Drug Safety Oversight Board; (3) the Agency actions for the COX-2 selective Nonsteroidal Anti-inflammatory Drugs (NSAIDs); and, (4) the risk management program for the isotretinoin products. I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Unrelated Data Safety and Monitoring Board	Affected Firm.	Earns less than \$10,001 a year.
Stock	Affected Firm.	Value between \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued. The public disclosure will be accomplished by reading this statement into the record and by FDA making a written copy publicly available at the time of the meeting. I understand that without public disclosure of these interests the waiver is not valid.

//S//
Signature of SGE

12/21/2005
Date